I期临床-话题@MedSci

#I期临床#

570篇内容 | 7039人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1653027, encodeId=c12a165302e51, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=III期临床：赛诺菲的CD38单抗Sarclisa显着降低了多发性骨髓瘤复发患者的死亡风险, objectType=article, longId=194121, objectId=ec9d1941215a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ec9d1941215a, replyNumber=0, likeNumber=51, createdTime=2020-10-02, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ec9d1941215a, moduleTitle=III期临床：赛诺菲的CD38单抗Sarclisa显着降低了多发性骨髓瘤复发患者的死亡风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ec9d1941215a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653066, encodeId=b9da165306614, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=COVID-19疫苗BNT162b2进入II / III期临床研究, objectType=article, longId=198193, objectId=ccfa198193ff, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ccfa198193ff, replyNumber=0, likeNumber=61, createdTime=2021-05-10, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ccfa198193ff, moduleTitle=COVID-19疫苗BNT162b2进入II / III期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ccfa198193ff)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653043, encodeId=3da9165304384, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=艾伯维的JAK抑制剂Rinvoq，III期临床显示出治疗特应性皮炎的潜力, objectType=article, longId=196190, objectId=6f67196190f1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6f67196190f1, replyNumber=0, likeNumber=67, createdTime=2021-05-28, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6f67196190f1, moduleTitle=艾伯维的JAK抑制剂Rinvoq，III期临床显示出治疗特应性皮炎的潜力, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6f67196190f1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653122, encodeId=ce3d16531229e, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=JAHA：二甲双胍治疗肺动脉高压的II期临床试验, objectType=article, longId=203254, objectId=0697203254d7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0697203254d7, replyNumber=0, likeNumber=73, createdTime=2021-08-19, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0697203254d7, moduleTitle=JAHA：二甲双胍治疗肺动脉高压的II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0697203254d7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653022, encodeId=345716530228c, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=诺和诺德的GLP-1激动剂semaglutide：非酒精性脂肪性肝炎的II期临床展现治疗潜力, objectType=article, longId=193810, objectId=97c7193810df, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=97c7193810df, replyNumber=0, likeNumber=66, createdTime=2020-08-06, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=97c7193810df, moduleTitle=诺和诺德的GLP-1激动剂semaglutide：非酒精性脂肪性肝炎的II期临床展现治疗潜力, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=97c7193810df)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653062, encodeId=b916165306285, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle= Lancet Diabetes Endo：Osilodrostat治疗库欣病III期临床获得成功, objectType=article, longId=198290, objectId=25df198290b5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=25df198290b5, replyNumber=0, likeNumber=56, createdTime=2020-12-09, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=25df198290b5, moduleTitle= Lancet Diabetes Endo：Osilodrostat治疗库欣病III期临床获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=25df198290b5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653031, encodeId=3d421653031a9, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=ASCO 2020：MEK162（贝美替尼）联合伊马替尼治疗晚期胃肠道间质瘤II期临床研究, objectType=article, longId=194645, objectId=1e85194645d2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1e85194645d2, replyNumber=0, likeNumber=60, createdTime=2021-05-06, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1e85194645d2, moduleTitle=ASCO 2020：MEK162（贝美替尼）联合伊马替尼治疗晚期胃肠道间质瘤II期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1e85194645d2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653120, encodeId=8ed71653120ca, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=阿斯利康的TSLP单抗tezepelumab治疗严重哮喘，III期临床成功, objectType=article, longId=203246, objectId=d0c62032469d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d0c62032469d, replyNumber=0, likeNumber=81, createdTime=2021-01-22, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d0c62032469d, moduleTitle=阿斯利康的TSLP单抗tezepelumab治疗严重哮喘，III期临床成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d0c62032469d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653060, encodeId=5e381653060a3, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=双重PPAR激动剂治疗非酒精性脂肪性肝炎：III期临床宣布失败, objectType=article, longId=197999, objectId=2c2219e999bb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2c2219e999bb, replyNumber=0, likeNumber=52, createdTime=2020-09-14, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2c2219e999bb, moduleTitle=双重PPAR激动剂治疗非酒精性脂肪性肝炎：III期临床宣布失败, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2c2219e999bb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653083, encodeId=3b701653083f2, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=NEJM：Tepotinib治疗MET外显子14跳跃突变非小细胞肺癌II期临床效果显著, objectType=article, longId=200217, objectId=5dcd20021e20, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5dcd20021e20, replyNumber=0, likeNumber=53, createdTime=2021-01-22, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5dcd20021e20, moduleTitle=NEJM：Tepotinib治疗MET外显子14跳跃突变非小细胞肺癌II期临床效果显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5dcd20021e20)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653100, encodeId=3565165310026, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=CAN04联合pembrolizumab治疗多种肿瘤：I期临床研究正在进行中, objectType=article, longId=201590, objectId=0d3c201590b5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0d3c201590b5, replyNumber=0, likeNumber=0, createdTime=2020-10-25, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0d3c201590b5, moduleTitle=CAN04联合pembrolizumab治疗多种肿瘤：I期临床研究正在进行中, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0d3c201590b5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653095, encodeId=26d4165309592, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=君实生物特瑞普利单抗一线治疗鼻咽癌III期临床研究PFS预估显著, objectType=article, longId=201382, objectId=2172201382b6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2172201382b6, replyNumber=0, likeNumber=119, createdTime=2020-10-06, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2172201382b6, moduleTitle=君实生物特瑞普利单抗一线治疗鼻咽癌III期临床研究PFS预估显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2172201382b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653144, encodeId=373a16531443c, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=LX9211治疗神经性疼痛，即将开展II期临床研究, objectType=article, longId=205264, objectId=56012052643d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=56012052643d, replyNumber=0, likeNumber=91, createdTime=2021-05-15, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=56012052643d, moduleTitle=LX9211治疗神经性疼痛，即将开展II期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=56012052643d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653050, encodeId=cd211653050bf, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=IL-6受体单抗Kevzara，治疗新冠病毒COVID-19的III期临床失败, objectType=article, longId=196982, objectId=867e19698235, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=867e19698235, replyNumber=0, likeNumber=57, createdTime=2021-03-09, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=867e19698235, moduleTitle=IL-6受体单抗Kevzara，治疗新冠病毒COVID-19的III期临床失败, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=867e19698235)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653018, encodeId=b33b1653018e7, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=获得1亿美元融资以及FDA快速通道指定后，荣昌生物再次获得FDA批准——启动抗HER2的ADC药物治疗尿路上皮癌的II期临床试验, objectType=article, longId=193386, objectId=63df19338615, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=63df19338615, replyNumber=0, likeNumber=65, createdTime=2021-04-05, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=63df19338615, moduleTitle=获得1亿美元融资以及FDA快速通道指定后，荣昌生物再次获得FDA批准——启动抗HER2的ADC药物治疗尿路上皮癌的II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=63df19338615)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653052, encodeId=51a716530522b, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Lancet：鲁索利替尼治疗白癜风II期临床获得成功, objectType=article, longId=197374, objectId=022919e37410, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=022919e37410, replyNumber=0, likeNumber=99, createdTime=2020-10-15, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=022919e37410, moduleTitle=Lancet：鲁索利替尼治疗白癜风II期临床获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=022919e37410)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653079, encodeId=ac8916530e946, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=SLEEP 2020：失眠患者的福音，Daridorexant的III期临床取得积极进展, objectType=article, longId=200035, objectId=4a2d20003511, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4a2d20003511, replyNumber=0, likeNumber=86, createdTime=2020-09-28, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4a2d20003511, moduleTitle=SLEEP 2020：失眠患者的福音，Daridorexant的III期临床取得积极进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4a2d20003511)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653064, encodeId=a01016530644c, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=LSALT肽（Metablok）治疗COVID-19：II期临床试验将在美国进行, objectType=article, longId=198327, objectId=861219832eff, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=861219832eff, replyNumber=0, likeNumber=78, createdTime=2020-09-27, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=861219832eff, moduleTitle=LSALT肽（Metablok）治疗COVID-19：II期临床试验将在美国进行, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=861219832eff)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653103, encodeId=52ad165310389, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=p38α抑制剂Neflamapimod治疗路易体痴呆症的II期临床成功，患者认知显着提高, objectType=article, longId=201946, objectId=8c3820194642, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8c3820194642, replyNumber=0, likeNumber=59, createdTime=2021-03-07, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8c3820194642, moduleTitle=p38α抑制剂Neflamapimod治疗路易体痴呆症的II期临床成功，患者认知显着提高, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8c3820194642)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1653080, encodeId=8f0716530807d, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=SLEEP 2020：DAYVIGO（lemborexant）治疗成年失眠，III期临床确认了其有效性和安全性, objectType=article, longId=200038, objectId=5362200038e5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5362200038e5, replyNumber=0, likeNumber=75, createdTime=2021-01-25, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5362200038e5, moduleTitle=SLEEP 2020：DAYVIGO（lemborexant）治疗成年失眠，III期临床确认了其有效性和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5362200038e5)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

I期临床

2020-05-29

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

III期临床：赛诺菲的CD38单抗Sarclisa显着降低了多发性骨髓瘤复发患者的死亡风险

2020-10-02

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

COVID-19疫苗BNT162b2进入II / III期临床研究

2021-05-10

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

艾伯维的JAK抑制剂Rinvoq，III期临床显示出治疗特应性皮炎的潜力

2021-05-28

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

JAHA：二甲双胍治疗肺动脉高压的II期临床试验

2021-08-19

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

诺和诺德的GLP-1激动剂semaglutide：非酒精性脂肪性肝炎的II期临床展现治疗潜力

2020-08-06

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Lancet Diabetes Endo：Osilodrostat治疗库欣病III期临床获得成功

2020-12-09

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

ASCO 2020：MEK162（贝美替尼）联合伊马替尼治疗晚期胃肠道间质瘤II期临床研究

2021-05-06

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

阿斯利康的TSLP单抗tezepelumab治疗严重哮喘，III期临床成功

2021-01-22

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

双重PPAR激动剂治疗非酒精性脂肪性肝炎：III期临床宣布失败

2020-09-14

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

NEJM：Tepotinib治疗MET外显子14跳跃突变非小细胞肺癌II期临床效果显著

2021-01-22

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

CAN04联合pembrolizumab治疗多种肿瘤：I期临床研究正在进行中

2020-10-25

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

君实生物特瑞普利单抗一线治疗鼻咽癌III期临床研究PFS预估显著

2020-10-06

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

LX9211治疗神经性疼痛，即将开展II期临床研究

2021-05-15

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

IL-6受体单抗Kevzara，治疗新冠病毒COVID-19的III期临床失败

2021-03-09

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

获得1亿美元融资以及FDA快速通道指定后，荣昌生物再次获得FDA批准——启动抗HER2的ADC药物治疗尿路上皮癌的II期临床试验

2021-04-05

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Lancet：鲁索利替尼治疗白癜风II期临床获得成功

2020-10-15

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

SLEEP 2020：失眠患者的福音，Daridorexant的III期临床取得积极进展

2020-09-28

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

LSALT肽（Metablok）治疗COVID-19：II期临床试验将在美国进行

2020-09-27

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

p38α抑制剂Neflamapimod治疗路易体痴呆症的II期临床成功，患者认知显着提高

2021-03-07

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

SLEEP 2020：DAYVIGO（lemborexant）治疗成年失眠，III期临床确认了其有效性和安全性

2021-01-25

科室
- - 订阅+
  - 更多科室
工具
服务